PUBLISHER: Grand View Research | PRODUCT CODE: 1631514
PUBLISHER: Grand View Research | PRODUCT CODE: 1631514
The global dermatological drugs market size is expected to reach USD 42.3 billion by 2030, expanding at a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global dermatological drugs market is expected to grow due to driving factors such as the availability of medical resources for detecting and treating skin diseases, nutritional deficiency due to unhealthy food habits, increasing awareness when it comes to lifestyle diseases, and increasing pollution levels, and lack of immunity in the population. Additionally, the rising per capita income and the increasing purchasing power are the driving forces in this market.
The acne segment is expected to expand with a CAGR of 10.5% from 2022 to 2028. Acne is a skin condition where dead skin and oil glands of skin glands are clogged, forming spots, pimples, and sometimes cysts. Additionally, infected hair follicles cause acne, which starts from the skin's pores. Acne causes bumps on the face, shoulders, chest, and back in the form of pimples, blackheads, and whiteheads. Acne can be cured, and the appearance of the skin can be improved with effective treatment from dermatologists, contributing to the dermatological drug market.
North America held the largest revenue share of more than 35% in 2021. The U.S. is positively contributing to the growth of the regional market. The presence of well-established pharmaceutical vendors is one of the key factors supporting the market growth. This region is one of the promising regions to launch new technology in terms of healthcare infrastructure and advanced research and development activities that help innovate and produce the most appropriate drugs to cure cancer. It is observed that in the region, there is a rapid shift in the healthcare industry to consumer-driven from traditional treatment for providing diagnosis and provision-based health services. Additionally, ease of availability of drugs and reimbursement policies for the patient in the healthcare industry contributes to driving the market in the region.